Treasury Issues Guidance on Qualifying Therapeutic Discovery Project Credit

Treasury Issues Guidance on Qualifying Therapeutic Discovery Project Credit

Publication

Related Solutions

A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
Clients’ legislative and regulatory concerns are best served by legal counsel with the deepest possible knowledge of the relevant channels of government. In legislative and regulatory matters, we advise clients and provide updates on IRS regulations and rulings in a variety of areas, including corporate tax, consolidated returns, pass-through entities, tax accounting, employee compensation, international taxation, excise taxes, financial institutions and exempt organizations. We also serve as legislative counsel to clients with respect to proposed federal tax legislation and represent clients in seeking favorable guidance from the IRS by obtaining private letter rulings regarding particular transactions or business structures, assisting clients with voluntary compliance and closing agreements and submitting comments on proposed regulations. Our experience extends to state and local levels as well, permitting a comprehensive approach to these issues. 
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
The Treasury Department has just released IRS Notice 2010-45, which establishes the qualifying therapeutic discovery project program for the 50% investment tax credit that was mandated by the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, the "Affordable Care Act"). This guidance provides information regarding the application process for the $1 billion of tax credits/grants under the program and the criteria to be considered.

Applications must be submitted by July 21, 2010, and a separate application must be submitted for each project. All applications submitted by that time will be treated as submitted on October 1, 2010, when the IRS will begin the formal 30-day review process for all applications. The application form, Form 8942, is not yet available but will be released by June 21, 2010.

We will provide a more comprehensive summary of this guidance shortly, but as this guidance has been highly anticipated, we wanted to provide the text of the guidance immediately.

Click here for the text of Notice 2010-45.

Read our prior alert discussing this program and other tax provisions affecting life sciences companies in the Affordable Care Act, Tax Provisions Affecting Life Sciences Companies in New Health Care Reform.

For more information on this or other tax matters, contact A. William Caporizzo. For more information on this or other life sciences matters, contact Cynthia T. Mazareas.

Authors

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel